|
Bioxel is a biopharmaceutical company focused on the manufacture and distribution of taxane pharmaceutical ingredients including paclitaxel, docetaxel, 9-DHB and 10-DAB. The Corporation has rolled out an integrated taxane manufacturing chain that complies with the pharmaceutical industry's highest standards. Drawing on its high-efficiency processes and exclusive technologies, Bioxel guarantees that its customers are supplied with high-quality taxane products on a reliable and sustainable basis.
Bioxel's customer base consists of generic and ethical pharmaceutical companies that develop and market taxane finished drug products. These drugs are widely used in oncology for the treatments of certain cancer types, including breast, lung, ovarian, stomach, prostate and head and neck cancers. Paclitaxel-coated stents are also used in cardiology to prevent post-operative restenosis following angioplasty procedures. The taxanes market is steadily growing, driven notably by the discovery of new therapeutic indications and the marketing of second generation drugs with improved efficacy and lower side effects.
The Corporation currently markets three products – natural paclitaxel, 9-DHB and 10-DAB – and is developing a portfolio of new products that include docetaxel, paclitaxel via a semi-synthetic route of production and innovative taxane-based drugs. |
Stock information
| Symbol |
TSX : BIP |
| Last trade |
0.10 |
| Open |
0.095 |
| Net change |
-0.005 |
| High |
0.10 |
| Low |
0.095 |
| 52 week range |
0.09 - 0.25 |
| Volume |
1,747 |
| As of |
2008-08-28
13:50 EST |
Quotes are delayed. For informational purposes only.
|
